Home › Companies › Madrigal Pharmaceuticals, Inc. › 2025-2026

Madrigal Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Madrigal Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-17 (Item 5.07 on EDGAR). Page generated 02 October 2026.

12Reported items
406Asset managers
3,234Fund votes
2026-06-17Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Madrigal Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Madrigal Pharmaceuticals, Inc.

These tallies are Madrigal Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Madrigal Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-17
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Julian C. Baker	17,363,250	--	--	2,227,734	1,731,844	Majority: yes
Elect Director: Daniel J. Brennan	19,469,200	--	--	121,784	1,731,844	Majority: yes
Elect Director: James M. Daly	18,921,185	--	--	669,799	1,731,844	Majority: yes
Proposal 2: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.	19,000,895	561,058	29,031	--	1,731,844	Majority: yes
Proposal 3: The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.	21,256,315	37,505	29,009	--	--	Majority: yes
Proposal 4: The Company's stockholders approved the 2026 Stock Plan.	19,118,851	446,394	25,739	--	1,731,844	Majority: yes
Proposal 5: The Company's stockholders approved the 2026 ESPP.	19,546,766	22,948	21,270	--	1,731,844	Majority: yes

This meeting is also recorded here as 2026-06-16; both records come from the same filing, so the date should be checked against it.

Source: Madrigal Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-17 — read the filing on EDGAR.

How asset managers voted at the Madrigal Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 406 asset managers that disclosed a Madrigal Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Madrigal Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 19,000,895AGAINST: 561,058

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”): 19,000,895 for, 561,058 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 23,041,918 outstanding shares: 82% for, 2% against (85% of the company cast a for/against vote).

The 403 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 99%

FOR: 98.5%AGAINST: 1.4%ABSTAIN: 0.0%NOT VOTED: 0.0%SPLIT: 0.0%

Largest asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Janus Henderson	3,280,810	0	For
Vanguard	2,391,520	1	For
BAKER BROS. ADVISORS LP	2,141,701	0	For
RTW INVESTMENTS, LP	1,993,687	0	For
Fidelity	1,127,725	4,388	For
JANUS INVESTMENT FUND	1,109,777	0	For
BlackRock	949,545	111,323	For
Wellington	663,183	0	For
PAULSON & CO. INC.	593,825	0	For
T. Rowe Price	566,199	500	For
Polar Capital Holdings Plc	547,284	0	For
State Street	504,156	251	For
Invesco	495,322	0	For
GEODE CAPITAL MANAGEMENT, LLC	458,203	0	For
Charles Schwab	436,249	0	For
Avoro Capital Advisors LLC	400,077	0	For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	288,709	0	For
American Century	248,113	0	For
LORD, ABBETT & CO. LLC	234,067	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	219,809	0	For
Lord Abbett	206,638	0	For
PICTET ASSET MANAGEMENT SA	173,138	0	For
Rock Springs Capital Management LP	170,999	0	For
Hood River Capital Management LLC	152,782	0	For
AllianceBernstein	149,971	0	For

Showing the 25 largest of 403 asset managers. See all 403 in the interactive database.

2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026

AUDIT-RELATEDMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 21,256,315AGAINST: 37,505

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 21,256,315 for, 37,505 against, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 23,041,918 outstanding shares: 92% for, 0.2% against (92% of the company cast a for/against vote).

The 108 asset managers below cast 99.9% of the shares they voted on this item FOR (7,160,987 for, 5 against).

FOR 99.9%

FOR: 7,160,987 (100.0%)AGAINST: 5 (0.0%)ABSTAIN: 3,508 (0.0%)NOT VOTED: 22 (0.0%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	2,236,360	0	0	For
JANUS INVESTMENT FUND	1,109,777	0	0	For
Fidelity	665,449	0	0	For
BlackRock	417,929	0	0	For
T. Rowe Price	224,867	0	0	For
Charles Schwab	217,759	0	0	For
Lord Abbett	206,638	0	0	For
Invesco	192,756	0	0	For
State Street	162,297	5	0	For
Erste Asset Management GmbH	130,210	0	0	For
American Century	115,417	0	0	For
Columbia Threadneedle	99,605	0	0	For
Manager Directed Portfolios	97,264	0	0	For
Jackson National	84,511	0	0	For
WILLIAM BLAIR FUNDS	65,128	0	0	For
Equitable	63,133	0	0	For
Goldman Sachs	58,004	0	0	For
TIAA	57,788	0	0	For
Brighthouse	39,802	0	3,508	For
HARBOR FUNDS	43,301	0	0	For
AIG/SunAmerica	43,063	0	0	For
ACAP Strategic Fund	39,609	0	0	For
Voya	38,676	0	0	For
BNY Mellon	38,557	0	0	For
Putnam	37,776	0	0	For

Showing the 25 largest of 108 asset managers. See all 108 in the interactive database.

3. Re-election of Class I directors: Daniel Brennan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 19,469,200WITHHELD: 121,784

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Daniel J. Brennan”): 19,469,200 for, 121,784 withheld, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 23,041,918 outstanding shares: 84% for, 0.6% withheld (85% of the company cast a for/withheld vote).

The 106 asset managers below cast 100% of the shares they voted on this item FOR (7,142,474 for, 0 against).

FOR 99.7%

FOR: 7,142,474 (99.7%)ABSTAIN: 21,026 (0.3%)NOT VOTED: 22 (0.0%)

Largest asset managers voting on “Re-election of Class I directors: Daniel Brennan” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,235,342	1,018	For
JANUS INVESTMENT FUND	1,109,777	0	For
Fidelity	665,449	0	For
BlackRock	417,929	0	For
T. Rowe Price	224,867	0	For
Charles Schwab	217,759	0	For
Lord Abbett	206,638	0	For
Invesco	192,756	0	For
State Street	162,302	0	For
Erste Asset Management GmbH	130,210	0	For
American Century	115,417	0	For
Columbia Threadneedle	99,605	0	For
Manager Directed Portfolios	97,264	0	For
Jackson National	84,511	0	For
WILLIAM BLAIR FUNDS	65,128	0	For
Equitable	63,133	0	For
Goldman Sachs	58,004	0	For
TIAA	57,788	0	For
Brighthouse	39,802	3,508	For
HARBOR FUNDS	43,301	0	For
AIG/SunAmerica	43,063	0	For
ACAP Strategic Fund	39,609	0	For
Voya	38,676	0	For
BNY Mellon	38,557	0	For
Putnam	37,776	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

4. Re-election of Class I directors: James Daly

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 18,921,185WITHHELD: 669,799

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: James M. Daly”): 18,921,185 for, 669,799 withheld, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 23,041,918 outstanding shares: 82% for, 3% withheld (85% of the company cast a for/withheld vote).

The 106 asset managers below cast 100% of the shares they voted on this item FOR (6,807,302 for, 0 against).

FOR 95%

FOR: 6,807,302 (95.0%)ABSTAIN: 356,198 (5.0%)NOT VOTED: 22 (0.0%)

Largest asset managers voting on “Re-election of Class I directors: James Daly” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,236,359	1	For
JANUS INVESTMENT FUND	1,109,777	0	For
Fidelity	665,449	0	For
BlackRock	417,929	0	For
T. Rowe Price	0	224,867	Abstain
Charles Schwab	217,759	0	For
Lord Abbett	206,638	0	For
Invesco	192,756	0	For
State Street	162,302	0	For
Erste Asset Management GmbH	130,210	0	For
American Century	115,417	0	For
Columbia Threadneedle	99,605	0	For
Manager Directed Portfolios	97,264	0	For
Jackson National	84,511	0	For
WILLIAM BLAIR FUNDS	65,128	0	For
Equitable	39,739	23,394	For
Goldman Sachs	58,004	0	For
TIAA	57,788	0	For
Brighthouse	30,562	12,748	For
HARBOR FUNDS	43,301	0	For
AIG/SunAmerica	43,063	0	For
ACAP Strategic Fund	39,609	0	For
Voya	38,676	0	For
BNY Mellon	38,557	0	For
Putnam	37,776	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

5. Re-election of Class I directors: Julian Baker

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 17,363,250WITHHELD: 2,227,734

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Julian C. Baker”): 17,363,250 for, 2,227,734 withheld, per its Form 8-K filed 2026-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 23,041,918 outstanding shares: 75% for, 10% withheld (85% of the company cast a for/withheld vote).

The 106 asset managers below cast 100% of the shares they voted on this item FOR (6,076,302 for, 0 against).

FOR 85%ABSTAIN 15%

FOR: 6,076,302 (84.8%)ABSTAIN: 1,087,198 (15.2%)NOT VOTED: 22 (0.0%)

Largest asset managers voting on “Re-election of Class I directors: Julian Baker” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	1,740,728	495,632	For
JANUS INVESTMENT FUND	1,109,777	0	For
Fidelity	665,449	0	For
BlackRock	417,929	0	For
T. Rowe Price	0	224,867	Abstain
Charles Schwab	217,759	0	For
Lord Abbett	206,638	0	For
Invesco	192,756	0	For
State Street	1,282	161,020	Abstain
Erste Asset Management GmbH	130,210	0	For
American Century	115,417	0	For
Columbia Threadneedle	99,605	0	For
Manager Directed Portfolios	97,264	0	For
Jackson National	84,511	0	For
WILLIAM BLAIR FUNDS	65,128	0	For
Equitable	39,739	23,394	For
Goldman Sachs	57,022	982	For
TIAA	57,788	0	For
Brighthouse	30,562	12,748	For
HARBOR FUNDS	43,301	0	For
AIG/SunAmerica	43,063	0	For
ACAP Strategic Fund	39,609	0	For
Voya	38,676	0	For
BNY Mellon	38,557	0	For
Putnam	37,776	0	For

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

6. APPROVAL OF MADRIGAL PHARMACEUTICALS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN

COMPENSATION

99.9% fund support · no official result

FOR 99.9%

The 103 asset managers below cast 99.9% of the shares they voted on this item FOR (7,003,016 for, 3,508 against).

FOR: 7,003,016 (99.9%)AGAINST: 3,508 (0.1%)NOT VOTED: 22 (0.0%)

Largest asset managers voting on “APPROVAL OF MADRIGAL PHARMACEUTICALS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	2,236,360	For
JANUS INVESTMENT FUND	1,109,777	For
Fidelity	665,449	For
BlackRock	417,929	For
T. Rowe Price	224,867	For
Charles Schwab	217,759	For
Lord Abbett	206,638	For
Invesco	192,756	For
State Street	162,302	For
American Century	115,417	For
Columbia Threadneedle	99,605	For
Manager Directed Portfolios	97,264	For
Jackson National	84,511	For
WILLIAM BLAIR FUNDS	65,128	For
Equitable	63,133	For
Goldman Sachs	58,004	For
TIAA	57,788	For
HARBOR FUNDS	43,301	For
AIG/SunAmerica	43,063	For
ACAP Strategic Fund	39,609	For
Voya	38,676	For
BNY Mellon	38,557	For
Putnam	37,776	For
JANUS ASPEN SERIES	36,744	For
AllianceBernstein	33,156	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

7. APPROVAL OF MADRIGAL PHARMACEUTICALS, INC. 2026 STOCK PLAN

COMPENSATION

99.2% fund support · no official result

FOR 99.2%

The 103 asset managers below cast 99.2% of the shares they voted on this item FOR (6,951,085 for, 55,439 against).

FOR: 6,951,085 (99.2%)AGAINST: 55,439 (0.8%)NOT VOTED: 22 (0.0%)

Largest asset managers voting on “APPROVAL OF MADRIGAL PHARMACEUTICALS, INC. 2026 STOCK PLAN” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,236,359	1	For
JANUS INVESTMENT FUND	1,109,777	0	For
Fidelity	665,449	0	For
BlackRock	417,929	0	For
T. Rowe Price	224,867	0	For
Charles Schwab	217,759	0	For
Lord Abbett	206,638	0	For
Invesco	192,756	0	For
State Street	162,297	5	For
American Century	115,417	0	For
Columbia Threadneedle	99,605	0	For
Manager Directed Portfolios	97,264	0	For
Jackson National	84,511	0	For
WILLIAM BLAIR FUNDS	65,128	0	For
Equitable	63,133	0	For
Goldman Sachs	58,004	0	For
TIAA	57,788	0	For
HARBOR FUNDS	43,301	0	For
AIG/SunAmerica	43,063	0	For
ACAP Strategic Fund	39,609	0	For
Voya	38,676	0	For
BNY Mellon	38,557	0	For
Putnam	0	37,776	Against
JANUS ASPEN SERIES	36,744	0	For
AllianceBernstein	33,156	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

8. Approve Omnibus Stock Plan

COMPENSATION

99.4% fund support · no official result

FOR 99.4%

The 6 asset managers below cast 99.4% of the shares they voted on this item FOR (169,443 for, 1,011 against).

FOR: 169,443 (99.4%)AGAINST: 1,011 (0.6%)

Largest asset managers voting on “Approve Omnibus Stock Plan” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Erste Asset Management GmbH	130,210	0	For
Brighthouse	24,846	0	For
Eversept Partners, LP	12,614	0	For
CLEARWATER INVESTMENT TRUST	1,772	0	For
VALUED ADVISERS TRUST	0	1,011	Against
Milliman Funds Trust	1	0	For

9. Approve Qualified Employee Stock Purchase Plan

COMPENSATION

100% fund support · no official result

FOR 100%

The 6 asset managers below cast 100% of the shares they voted on this item FOR (170,454 for, 0 against).

FOR: 170,454 (100.0%)

Largest asset managers voting on “Approve Qualified Employee Stock Purchase Plan” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
Erste Asset Management GmbH	130,210	For
Brighthouse	24,846	For
Eversept Partners, LP	12,614	For
CLEARWATER INVESTMENT TRUST	1,772	For
VALUED ADVISERS TRUST	1,011	For
Milliman Funds Trust	1	For

10. Adopt Employee Stock Purchase Plan

CAPITAL STRUCTURE

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (1,004 for, 0 against).

FOR: 1,004 (100.0%)

Largest asset managers voting on “Adopt Employee Stock Purchase Plan” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
AMERICAN PENSION INVESTORS TRUST	500	For
McGowan Group Asset Management, Inc.	500	For
MARCO INVESTMENT MANAGEMENT LLC	4	For

11. Adopt Stock Option Plan

COMPENSATION

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,000 for, 0 against).

FOR: 1,000 (100.0%)

Largest asset managers voting on “Adopt Stock Option Plan” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
AMERICAN PENSION INVESTORS TRUST	500	0	0	0	For
McGowan Group Asset Management, Inc.	500	0	0	0	For

12. Election of Directors (Full Slate)

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,000 for, 0 against).

FOR: 1,000 (100.0%)

Largest asset managers voting on “Election of Directors (Full Slate)” at Madrigal Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
AMERICAN PENSION INVESTORS TRUST	500	0	0	0	For
McGowan Group Asset Management, Inc.	500	0	0	0	For

Largest Madrigal Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Madrigal Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 23,041,918 shares outstanding at the time of that meeting.

Top Madrigal Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Janus Henderson	14.24%
2	Vanguard	10.38%
3	BAKER BROS. ADVISORS LP	9.29%
4	RTW INVESTMENTS, LP	8.65%
5	Fidelity	4.91%
6	JANUS INVESTMENT FUND	4.82%
7	BlackRock	4.60%
8	Wellington	2.88%
9	PAULSON & CO. INC.	2.58%
10	T. Rowe Price	2.46%

Reported Madrigal Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Madrigal Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Avoro Capital Advisors LLC	10.07%	DEF14A
Baker Bros. Advisors LP and affiliates	10.07%	DEF14A
Julian Baker	10.07%	DEF14A
JANUS HENDERSON GROUP PLC	8.76%	13G
RTW Investments, LP and affiliates	8.65%	DEF14A
Vanguard Group	7.85%	13F
Paul Friedman, M.D.	7.72%	DEF14A
Rebecca Taub, M.D.	7.72%	DEF14A
Paulson & Co. Inc. and affiliates	7.41%	DEF14A
BlackRock	6.77%	13F

Percentages above are of 23,041,918 shares outstanding, as reported by Madrigal Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Madrigal Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Madrigal Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 406 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,234 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Madrigal Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-17.

Madrigal Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).